In collaboration with Starpharma, we have shown that dendrimer-based nanomaterials have great potential as a means of enhancing the activity and reducing the side effects of highly potent, but toxic drugs such as anticancer agents. Here we seek to evaluate 'next generation' dendrimers where site-specific delivery is achieved by conjugation to a molecularly specific targeting group. In particular we will explore the relationship between the molecular architecture of a series of targeted dendrimers and their cellular and in vivo fate. Successful project completion will significantly enhance our ability to rationally develop novel dendritic nanomaterials with applications in fields including drug delivery, imaging, diagnostics and sensors.
|Effective start/end date||1/07/13 → 31/12/18|
- Australian Research Council (ARC): AUD547,863.00